Following high response rates to systemic therapies like EV Pembro, using radiation for bladder preservation is now questioned. It may constitute overtreatment by radiating a now cancer-free organ, while providing no benefit for the systemic micrometastases that are the primary driver of mortality.

Achieving a pathologic complete response (path CR) in the bladder after neoadjuvant therapy is a marker of drug efficacy, not a signal to stop treatment. Because patients die from metastatic, not local, disease, a path CR should be seen as a reason to "double down" on the effective systemic therapy to eradicate micrometastases.

In the SURE-01 trial, nearly a third of patients declined radical cystectomy after strong responses to sacituzumab govitecan. This patient-driven decision highlights a significant, growing interest in bladder preservation, pushing the field to validate less invasive approaches for select patients.

Neoadjuvant EV-Pembro yields pathologic complete response rates near 60% in muscle-invasive bladder cancer. This high efficacy has prompted multiple large-scale clinical trials to test whether radical cystectomy can be safely avoided in select patients, a potentially practice-defining change.

As oncology moves toward bladder-sparing approaches, even highly effective systemic therapies won't be enough. To prevent local relapse and truly avoid cystectomy, a bladder-directed component, such as an intravesical therapy, will be a necessary part of the long-term treatment strategy.

With highly effective neoadjuvant therapies now available, the surgeon's role in muscle-invasive bladder cancer is evolving. They are moving from being the primary decider and treater to being a key manager of a 'perioperative bundle,' where their first goal is often to get patients to medical oncology for systemic treatment.

Despite excellent responses to systemic therapy in very locally advanced bladder cancer, some experts still advocate for surgery. They argue that even with a complete radiological response, a surgical intervention might represent the only "window of opportunity for cure" by eradicating residual microscopic disease and should remain a key discussion point.

High relapse rates (~70%) in surgery-alone arms of recent trials suggest most patients with muscle-invasive bladder cancer (MIBC) already have micrometastatic disease. This reframes the disease, prioritizing early systemic therapy over immediate surgery to achieve control and potential cure.

Expert consensus shows a major paradigm shift: perioperative systemic therapy (like EV-Pembro, scoring 2.9) is the undisputed standard for muscle-invasive bladder cancer. Approaches starting with cystectomy alone now score below 1.8, formally branding them as inferior options.